TAVI SYSTEM
TAVI
Kontrollierte Freisetzung. Überzeugende klinische Ergebnisse.
Entwickelt für zukünftige Interventionen.
Durchdacht in jedem Detail
Das Navitor™ Transkatheter-Aortenklappen-Implantationssystem (TAVI-System) wurde für den minimalinvasiven Herzklappenersatz bei schwerer Aortenstenose konzipiert.
Im Mittelpunkt stehen eine stabile Klappenpositionierung, überzeugende klinische Ergebnisse und die Berücksichtigung zukünftiger Koronarinterventionen.
SEHEN SIE SICH DIE LIVE-FÄLLE AN:
Live Case: EACTS Techno College Live Case aus dem Rigshospitalet Kopenhagen
Für die Anforderungen moderner TAVI-Verfahren
Das Navitor™ TAVI-System kombiniert eine präzise Implantation mit einer ausgezeichneten hämodynamischen Performance und einer langfristig ausgelegten Klappenfunktion.
Sein Design unterstützt eine kontrollierte Freisetzung und eine zuverlässige Positionierung der Klappe.
Merkmale der Navitor Vision
Präzision in jedem Detail
Mit effektiver Abdichtung, sehr guter hämodynamischer Performance und einem Design zur Unterstützung des koronaren Zugangs vereint die Navitor™ Vision* Klappe zentrale Eigenschaften moderner TAVI-Systeme.
HERVORRAGENDE ERGEBNISSE IN KLINISCHEN STUDIEN | 30 TAGE1,2
ENTDECKEN SIE DIE FUNKTIONEN UND VORTEILE DES NAVITOR™ TAVI SYSTEMS.
TV
CONNEXT TV
ESC 2026 | Cardiac imaging in aortic stenosis
ESC 2026 | Aortic stenosis CT assessment
ESC 2026 | Aortic stenosis CT assessment
ESC 2026 | Cardiac imaging in aortic stenosis
Procedural tip & tricks with Navitor across all valve sizes
Transcatheter Aortic Valves Implant
1-year VANTAGE TAVI outcomes in low/intermediate-risk patients
TAVI in complex anatomies
AI-enabled procedural learning
Case planning for lifetime management
- Søndergaard L, Walton AS, Worthley SG, et al. Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG study. Eurointervention 2023;EIJ-D-22-01108. eurointervention.pcronline.com/article/thirty-day-and-one-year-outcomes-of-thenavitor-transcatheter-heart-valve-in-patients-with-aortic-stenosis-the-prospective-multicentre-global-portico-ng-study.
- Søndergaard, L. 30-day outcomes from a next generation TAVI device with an active sealing cuff. Presented at: EuroPCR conference; May 18–20, 2021.
- Pibarot P, Hahn RT, Weissman NJ, et al. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. 2015;8(3):340–360.
doi.org/10.1016/j.jcmg.2015.01.008. - Frater RWM, Seifter E, Liao K, et al. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. Austin, TX: Silent Partners Inc; 1997:105–114.
- Kelly SJ, Ogle, MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Society for biomaterials. Sixth World Biomaterials Congress Transaction. 2000;13534.
- Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation.
1997;95(2):479–488. doi.org/10.1161/01.CIR.95.2.479. - Vyavahare N, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577–585.https://doi.org/10.1002/(SICI)1097-4636(19980615)40:4%3C577::AID-JBM9%3E3.0.CO;2-C.
- Gross JM. Calcification of bioprosthetic heart valves and its assessment. J Thorac Cardiovasc Surg. 2003;125:S6–8. doi.org/10.1067/mtc.2003.208.
- Tod TJ, Dove JS. The association of bound aldehyde content with bioprosthetic tissue calcification. J Mater Sci: Mater Med. 2016;27:8.
doi.org/10.1007/s10856-015-5623-z. - Meuris B, De Praetere H, Strasly M, et al. A novel tissue treatment to reduce mineralization of bovine pericardial heart valves. JTCVS. 2018;156(1):197–206. doi.org/10.1016/j.jtcvs.2018.01.099.
- Data on file at Abbott. 90664679
- Medtronic CoreValve Evolut‡ PRO Instructions for Use.
- Navitor™ TAVI System Instructions for Use.
- Boston Scientific ACURATE neo2‡ Instructions for Use.
- Boston Scientific iSleeve‡ Instructions for Use.
- Edwards Sapien‡ 3 Instructions for Use.
- Koehler Sapien‡ 3 eSheath OD BMRI 2015.
- Abbott data on file 90368819.
- Abbott data on file 90346620.
- Portico™ TAVI System Instructions for Use
‡Indicates a third-party trademark, which is the property of its respective owner.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available)or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.